Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.48 |
| ▸ | MALT1 | Q9UDY8 | 5/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | F13A1 | P00488 | 1/20 | 0.43 |
| ▸ | TGM2 | P21980 | 1/20 | 0.43 |
| ▸ | TGM1 | P22735 | 1/20 | 0.43 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10278274 | 0.95 | TRPV1 (0.45) | TRPV1MALT1HSD11B1F13A1TGM2 | |
| SCHEMBL4874028 | 0.87 | MALT1 (0.53) | TRPV1MALT1 | |
| SCHEMBL27684336 | 0.87 | MALT1 (0.47) | TRPV1MALT1CYP3A4CYP2D6TSHR | |
| SCHEMBL10278269 | 0.86 | GRIN2D (0.42) | MALT1HSD11B1CYP3A4CYP2D6TSHR | |
| SCHEMBL3436522 | 0.84 | TRPV1 (0.47) | TRPV1MALT1HSD11B1F13A1TGM2 | |
| SCHEMBL3435616 | 0.82 | CYP1A2 (0.59) | HSD11B1CYP2C19 | |
| SCHEMBL10276904 | 0.82 | L3MBTL1 (0.41) | MALT1HSD11B1CYP3A4CYP2D6TSHR | |
| SCHEMBL3436585 | 0.81 | TRPV1 (0.45) | TRPV1MALT1HSD11B1F13A1TGM2 | |
| SCHEMBL3436533 | 0.79 | TRPV1 (0.46) | TRPV1MALT1HSD11B1F13A1TGM2 | |
| SCHEMBL3954751 | 0.79 | GRIN2D (0.40) | MALT1HSD11B1CYP3A4CYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
| EP-2009005-A1 | AZOLECARBOXAMIDE DERIVATIVE | Astellas Pharma Inc. (JP) | 2008-12-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | GPR17, NTRK1, TRPV1 | TRPV1 3/4885MALT1 1638/4885HSD11B1 3972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.